The Metabolic Effects of Ginseng Oligopeptide Preparation on Non- Alcoholic Fatty Liver Disease With Obesity: a Randomized Controlled Double-blind Trial
NCT ID: NCT06167902
Last Updated: 2023-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
200 participants
INTERVENTIONAL
2023-12-25
2025-12-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ginseng oligopeptide group
Ginseng oligopeptide (Ginseng extract）
The experimental group was given ginseng oligopeptide preparation 1.2g per day orally.
The placebo group
Maltodextrin
The control group was treated with placebo maltodextrin 1.2g/d
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ginseng oligopeptide (Ginseng extract）
The experimental group was given ginseng oligopeptide preparation 1.2g per day orally.
Maltodextrin
The control group was treated with placebo maltodextrin 1.2g/d
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18-65 years old;
* ALT, AST, GGT≤2×Upper Limit Of Normal（ULN）;
* BMI≥28Kg/㎡;
* Patients signed the relevant informed consent on a voluntary basis.
Exclusion Criteria
* Allergic to the ingredients of ginseng oligopeptide preparation;
* Serum ALT, AST, GGT\>2ULN;
* Currently taking oral hepatoprotective drugs such as reduced glutathione, polyene phosphatidylcholine, and silibinin, etc.;
* Subjects participating in other clinical trials;
* Pregnant or lactating women;
* Complicated with serious diseases of the digestive system or other systems, such as chronic gastrointestinal diseases and chronic diseases causing digestive malabsorption,Kidney disease, hematological system or autoimmune diseases;
* Other populations that were deemed by the investigators to be ineligible for the trial may reduce or complicate enrollment patients with chemotherapy.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking Union Medical College Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ginseng oligopeptide 1.0
Identifier Type: -
Identifier Source: org_study_id